Approach and Management of Hypertension After Kidney Transplantation

Medicine and Dentistry

• Blood Pressure 100%
• Kidney Transplantation 100%
• Cardiovascular System 100%
• Kidney Denervation 100%
• Kidney Graft 66%
• Antihypertensive Agent 66%
• Obstructive Sleep Apnea 66%
• Renal Artery Stenosis 66%
• Nephrectomy 66%
• Resistant Hypertension 66%
• Fibroblast Growth Factor 23 66%
• Diabetes Mellitus 33%
• Allograft 33%
• Intravenous Drug Administration 33%
• Cohort Effect 33%
• Chronic Kidney Disease 33%
• Hyperlipidemia 33%
• All Cause Mortality 33%
• Calcineurin Inhibitor 33%
• Volume Overload 33%
• Chronic Allograft Nephropathy 33%
• Blood Pressure Monitoring 33%
• Clinician 33%
• Metabolic Disorder 33%
• Immunosuppressive Drug 33%
• Comorbidity 33%

Keyphrases

• Kidney Transplantation 100%
• Hypertension Management 100%
• Posttransplant Hypertension 100%
• Hypertension 42%
• Post-transplant Period 42%
• Renal Denervation 42%
• Transplantation 28%
• Fibroblast Growth Factor 23 (FGF23) 28%
• Etiology 28%
• Obstructive Sleep Apnea 28%
• Antihypertensive Medication 28%
• Blood Pressure Target 28%
• Resistant Hypertension 28%
• Transplant Renal Artery Stenosis 28%
• Native Nephrectomy 28%
• Epidemiology 14%
• Type 1 Diabetes Mellitus (T1DM) 14%
• Obesity 14%
• Cardiovascular Outcomes 14%
• Chronic Kidney Disease 14%
• Donor Kidney 14%
• Kidney Transplant 14%
• Blood Pressure 14%
• Mechanism of Action 14%
• Immunosuppressive Medication 14%
• Treatment Options 14%
• Allograft 14%
• Metabolic Disease 14%
• Inhibiting Effect 14%
• Kidney Transplant Recipients 14%
• Pretransplant 14%
• Immediate Early 14%
• Complex Patients 14%
• Appropriate Management 14%
• All-cause Mortality 14%
• Procedural Complications 14%
• Transplant Population 14%
• Non-pharmaceutical Interventions 14%
• Pharmacological Therapy 14%
• Non-pharmacological 14%
• Survival Outcomes 14%
• Professional Societies 14%
• Calcineurin Inhibitors 14%
• Immunologic Factors 14%
• Volume Overload 14%
• Chronic Renal Allograft Dysfunction 14%
• Cardiovascular Comorbidities 14%
• 24-h Ambulatory Blood Pressure Monitoring 14%
• Intravenous Fluid Administration 14%
• Native Kidney 14%
• Blood Pressure Management 14%
• Non-transplant Patients 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Sleep Disordered Breathing 100%
• Antihypertensive Agent 100%
• Kidney Artery Stenosis 100%
• Resistant Hypertension 100%
• Fibroblast Growth Factor 23 100%
• Chronic Kidney Failure 50%
• Immunosuppressive Agent 50%
• All Cause Mortality 50%
• Hyperlipidemia 50%
• Infusion Fluid 50%
• Calcineurin Inhibitor 50%
• Chronic Allograft Nephropathy 50%
• Diabetes Mellitus 50%
• Comorbidity 50%
• Diseases 50%